Selecta Biosciences (SELB) Investor Presentation - Slideshow

SEL-212 for Chronic Refractory Gout - SEL-212 addresses a $1B+ chronic refractory gout market with high unmet need[5,15] - In a Phase 2 dose ranging study, 66% (21/32) of patients achieved SUA levels <6 mg/dL after 20 weeks of once-monthly SEL-212 treatment[17,18] - The company is conducting a head-to-head trial (COMPARE) of SEL-212 against pegloticase in chronic refractory gout patients, with approximately 150 patients enrolled[5,32] - Top-line data from the COMPARE trial is expected in 3Q 2020, and a Phase 3 pivotal program against placebo is planned for 2H 2020[5,64] ImmTOR Platform in Gene Therapy - The company's ImmTOR platform aims to mitigate Neutralizing Antibody (Nab) formation, potentially enabling re-dosing of AAV gene therapies[5] - Preclinical studies suggest ImmTOR can induce antigen-specific immune tolerance, preventing NAb development in mice treated with ImmTOR+AAV vector[42] - A license agreement with AskBio includes upfront payments of $7 million and potential clinical and sales milestone payments of $237 million for Pompe disease[50] - The company expects to commence a human POC trial under the AskBio collaboration in 4Q 2020[64] Financial Status - As of March 31, 2020, the company had $74.264 million in cash, cash equivalents, marketable securities, and restricted cash[61]